Contineum Therapeutics focuses on creating precision small molecules that seek to alter the course of clinical impairment, specializing in the neuroscience, inflammation, and immunology sectors.

Contineum Therapeutics

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Contineum Therapeutics, Inc. Class A Common Stock

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 24, 2024 4:19 PM	f66cc2df
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 24, 2024 4:19 PM	b837ea22
crunchbase trigger	general	Nov 27, 2024 12:50 PM	23a9dcce
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Oct 24, 2024 4:19 PM	5b3baf72
news basic	general	Oct 24, 2024 4:19 PM	325f0ea5
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CTNM

COM:CONTINEUM-TX

Contineum Therapeutics

Last Close

7.69

14/02 21:00

Market Cap

541.73M

Beta: -

Volume Today

47.20K

Avg: -